Skip to main content

Table 1 Demographic and clinical characteristics

From: Feasibility of a tailored home-based exercise intervention during neoadjuvant chemotherapy in breast cancer patients

  Overall n = 19 Control n = 10 Intervention n = 9 P-value
Age (years) 49.4 ± 10.5 51.5 ± 9.5 47.0 ± 11.7 0.37
Race n, (%)     
 White 13 (69%) 8 (80%) 5 (56%) 0.40
 Black 5 (26%) 2 (20%) 3 (33%)  
 Other 1 (5%) 0 (0%) 1 (11%)  
Ethnicity n, (%)     
 Not hispanic 19 (100%) 10 (100%) 9 (100%)  
Working status n, (%)     
 Full time (at least 1 job) 12 (63%) 7 (70%) 5 (56%) 0.73
 Part time (no FT) 4 (21%) 2 (20%) 2 (22%)  
 Other 3 (16%) 1 (10%) 2 (22%)  
Household income n, (%)     
 0–49,999 5 (26%) 3 (30%) 2 (22%) 0.18
 50,000–75,000 4 (21%) 3 (30%) 1 (11%)  
 75,001–125,000 6 (32%) 1 (10%) 5 (56%)  
 125,000+ 4 (21%) 3 (30%) 1 (11%)  
Education n, (%)     
 HS/some college 4 (21%) 2 (20%) 2 (22%) 0.74
 Associates/Bachelors 8 (42%) 5 (50%) 3 (33%)  
 Graduate school 7 (37%) 3 (30%) 4 (44%)  
Partnered n, (%)     
 Not partnered 5 (26%) 4 (40%) 1 (11%) 0.15
 Coupled 14 (74%) 6 (60%) 8 (89%)  
Smoking status n, (%)     
 Non or ex-smoker 16 (84%) 9 (90%) 7 (78%) 0.53
 Current smoker 3 (16%) 1 (10%) 2 (22%)  
Site n, (%)     
 CCC 6 (32%) 3 (30%) 3 (33%) 0.97
 CI 9 (47%) 5 (50%) 4 (44%)  
Community 4 (21%) 2 (20%) 2 (22%)  
Stage n, (%)     
 1 4 (21%) 2 (20%) 2 (22%) 0.93
 2 10 (53%) 5 (50%) 5 (55%)  
 3 5 (26%) 3 (30%) 2 (22%)  
Tumor type n, (%)     
 HR+ HER2+ 6 (32%) 4 (40%) 2 (22%) 0.81
 HR+ HER2− 2 (11%) 1 (10%) 1 (11%)  
 HR-HER2+ 8 (42%) 4 (40%) 4 (44%)  
 HR-HER2− 3 (16%) 1 (10%) 2 (22%)  
Chemo n, (%)     
 ACT 5 (26%) 2 (20%) 3 (33%) 0.51
 TCHP 9 (47%) 6 (60%) 3 (33%)  
 ACTH 5 (26%) 2 (20%) 3 (33%)  
  1. Data presented as mean ± SD for continuous data and n (%) for categorical data. Abbreviations include: Comprehensive Cancer Center (CCC), Cancer Institute (CI), hormone receptor (HR), human epidermal growth factor receptor 2 (HER2), ACT denotes Adriamycin® (doxorubicin), cyclophosphamide, and Taxol® (paclitaxel), TCHP denotes Taxotere® (docetaxel), carboplatin, Herceptin® (trastuzumab), Perjeta® (pertuzumab)